Dr Fratazzi devised the concept of a Strategic Clinical Innovation Organization (SCIO) and founded the first SCIO –Boston Biotech Clinical Research (BBCR), LLC in 2009, with the objective of actively contributing to innovation in clinical research developing strategic clinical regulatory pathways to product approval.
Dr. Candida Fratazzi expertise includes Drug and Device as well as Combination Products. She is an Immunologist with over 15 years of experience in Orphan petitions and phase 1-4 clinical programs. Known for her excellent analytical abilities and problem solving skills.
Experienced in mentoring and managerial roles. Appreciated leader, team player, and communicator. Worked on several medical affair projects facilitating products transition from research to post-marketing. Has extensive drug safety and risk management experience. Dr Fratazzi helps international companies to enter the US and EU markets.